A follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.
Mark Trusheim
Advertisement
Articles by Mark Trusheim
A look at two surveys that reveal payer perspectives regarding current and future management of high-cost durable therapies with one-time administration.
Advertisement
Latest Updated Articles
Payer Perspectives on Reimbursement of One-Time High-Cost Durable TherapiesPublished: January 9th 2020 | Updated:
Payer Perspectives on Gene Therapy ReimbursementPublished: April 8th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
4
Roundup: Pharma Industry Raises Funding Aimed at Advancing the Development and Testing of Rare Disease Treatments
5
